NRC	<b>FORM</b>	374
-----	-------------	-----

## U.S. NUCLEAR REGULATORY COMMISSION

OF **PAGES** Amendment No. 28

MATERIALS LICENSE Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below/ In accordance with the letter dated Licensee January 23, 2007, 3. License number 13-16286-01 is amended in Riverview Hospital its entirety to read as follows: 4. Expiration date October 31, 2010 2. 395 Westfield Road 5. Pecket No. 030-10729 EAR P.O. Box 220 Reference N Noblesville, IN 46060 Chemical and/or physical form Maximum amount that licensee may Byproduct, source, and/or special Dossess at any one time under this nuclear material **ficense** Any byproduct material? As needed permitted by 10 CFR 36.100 B. Any byproduct material ≴s needed permitted by 10 CFR 35.200 As needed (not to exceed C. Any byproduct material permitted by 10 CFR 35.300 one curie of I-131) D As needed D. Any byproduct material \square permitted by 10 CFR 31.1. Total activity not to exceed E. Any byproduct material American Scientific, Inc 1120 millicuries. permitted by 10 CFR 35.500 Model No. 13601 (Gadolinium-153 not to Isotope Products exceed 250 millicuires per Laboratories Model No. source and cesium-137 not to exceed 30 millicuries per HEG-137) source). Two shields, not to exceed Uranium (depleted in F. Plated metal 22 kilograms (25 pounds) uranium-235)

## Authorized Use:

- Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION PAGE 2 of 4	PAGES								
License Number 13-16286-01									
MATERIALS LICENSE  Docket or Reference Number 030-10729									
SUPPLEMENTARY SHEET  Amendment No. 28	<del></del>								
American vo. 25									
D. <u>In vitro</u> studies.									
E. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).									
F. For use as shielding in an ADAC Laboratories Attenuation Correction Model MCD/AC Device.	F. For use as shielding in an ADAC Laboratories Attenuation Correction Model MCD/AC Device.								
CONDITIONS									
R R E G // 10. Licensed material shall be used only at the licensee's facilities located at 395 Westfield Road, Noblesville,									
Indiana.	,								
11. The Radiation Safety Office for this license is Patrick J. Byrne, D.A.B.R.									
12. Licensed material is only authorized for use by, or under the supervision of:									
	A. Individuals permitted to work as an authorized user in advortance with 10 CFR 35.13 and 35.14.								
B. The following individuals are authors.									
Authorized Users  Market all and Use									
Linda Lau, M.D. 35, 100 35, 100 35, 35, 300, 35, 500, and 31.11.									
Anthony J. Cossell, M.D. 10 CFR 35.200, 35.500, and 31.11.									
William E. McGraw, M.D. 20 CFR 35.100 and 35.200.									
John Mark Michael, M.D. 10 CFR 35.100, 35.200 and 35.300.									
Richard L. Hallett, M.D. 10 CFR 35.100, 35.200 and 35.300.									
Peter D. Arfken, M.D. 10 CFR 35.100, 35.200 and 35.300.									
John A. Morton, M.D. 10 CFR 35.100, 35.200, 35.300 and 31.11.									
Margaret Brengle, M.D. 10 CFR 35.100 and 35.200.									
Jeffrey I. Reider, M.D. 10 CFR 35.100 and 35.200.									
Homer F. Beltz, M.D. 10 CFR 35.100 and 35.200.									
Michael S. Skulski, M.D. 10 CFR 35.100 and 35.200.									
Richard T. Beeler, M.D. 10 CFR 35.100, 35.200 and 35.300.									

NRC FOR	M 374A U.S. NUCLEAR REGU	JLATORY COMMISSION		PAGE	3	of 4	F	PAGES
		License Number 13-16286-01						
	MATERIALS LICENSE SUPPLEMENTARY SHEET		Docket or Reference Number 030-10729	•				
<del></del>			Amendment No. 28					
	Steven A. Fritsch, M.D.	10 CFR 35.100 an	d 35.200.					
	Frank J. Pistoia, M.D.	10 CFR 35.100 an	d 35.200.					
	Michael A. Kuharik, M.D.	10 CFR 35.100 an	d 35.200					
	Janalyn P. Ferguson, M.D.	10 CFR 35.100 an	d 35.200.					
	Jane S. Mitchell, M.D.	10 CFR 35.100 and						
	Jack J. Moss, M.D.	10 CFR 35.100 an	d \$5,200.					
	Lori J. Wells, M.D.	10 CFR 35.100 and	d 35.200.					
	Eric D. Elliott, M.D.	10 CFR 35.100 and	d 35.290.					
	Charles A. Lerner, W.D.	0 CFR 35:100 am	<b>33520</b> 0.					
	Thomas Hagman, M.D.	CFR, 85,150, 35	2.0 and 35.300.					
	Brian J. Weigel, M.D.		200 ana 35.300.≥					
	Jack M. Drew, M.D.	10 3 <b>41 35</b> .100 3	200 35.300					
	David R. Gulliver, M.D.	+ CFP - 35	and 35.300.					
	J. Michael Phelps, Jr., M.D.	10 CFR 35.100, 35	5.200, an <b>d</b> 35.300 (exc	luding	iodir	ne-13	1 fo	r
	Timothy L. Davis, M.D.	hyroid carcinoma). 10 CFR 35.100, 35 thyroid carcinoma).	5.200, and 35.300 (exc	luding	iodir	ne-13	1 fo	r
	Vincent P. Mathews, M.D.	10 CFR 35.100 and	d 35.200.					
	Theodore P. Labus, M.D.	10 CFR 35.100, 35	i.200 and 35.300.					
	Cristina M. Shinaver, M.D.	10 CFR 35.100, 35	.200 and 35.300.					
mate	ddition to the possession limits in Ite erial to quantities below the minimul ommissioning financial assurance.					n of I	icen	sed

14. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

Region III